Organization and Summary of Significant Accounting Policies - Additional Information (Detail) |
9 Months Ended |
|---|---|
Sep. 30, 2015 | |
| Evofosfamide | Collaborative Arrangement Product Agreement | Merck KGaA | |
| Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] | |
| Percentage share of eligible worldwide development expenses | 70.00% |
| X | ||||||||||
- Definition Merck KGaA's percentage share of worldwide development expenses. No definition available.
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|